Kupando

Kupando develops a dual TLR 4 and 7 agonist that stimulates innate immune and trained immunity for use against solid tumours and infectious disease. The Schonefeld based biopharmaceutical company raised an additional 10 million euro in March 2026, taking its Series A total to 23 million euro, to fund a Phase 1b study of lead candidate KUP101.